|
gptkbp:instanceOf
|
antineoplastic agent
vinca alkaloid
|
|
gptkbp:administeredBy
|
intravenous injection
|
|
gptkbp:approvedBy
|
1963 (US)
|
|
gptkbp:ATCCode
|
L01CA02
|
|
gptkbp:brand
|
gptkb:Oncovin
gptkb:Vincasar_PFS
|
|
gptkbp:CASNumber
|
57-22-7
|
|
gptkbp:category
|
natural product
antineoplastic agent
mitotic inhibitor
|
|
gptkbp:chemicalFormula
|
C46H56N4O10
|
|
gptkbp:color
|
white to off-white powder
|
|
gptkbp:contraindication
|
gptkb:Charcot-Marie-Tooth_disease
|
|
gptkbp:derivedFrom
|
gptkb:Catharanthus_roseus
|
|
gptkbp:discoveredBy
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:discoveredIn
|
1961
|
|
gptkbp:eliminationHalfLife
|
19-155 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
vincristine
|
|
gptkbp:KEGGID
|
D08667
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits microtubule formation
|
|
gptkbp:MeSH_ID
|
D014774
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
824.978 g/mol
|
|
gptkbp:notAdministeredBy
|
intrathecal
|
|
gptkbp:origin
|
plant-derived
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL521
5978
DB00541
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
gptkb:SIADH
constipation
hair loss
peripheral neuropathy
bone marrow suppression
jaw pain
|
|
gptkbp:solubility
|
soluble in water
|
|
gptkbp:toxicity
|
neurotoxicity
fatal if given intrathecally
|
|
gptkbp:UNII
|
6T6U180Z8Q
|
|
gptkbp:usedFor
|
gptkb:neuroblastoma
gptkb:Wilms_tumor
gptkb:rhabdomyosarcoma
gptkb:Ewing_sarcoma
leukemia
Hodgkin lymphoma
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
included
|
|
gptkbp:bfsParent
|
gptkb:CYP3A4
|
|
gptkbp:bfsLayer
|
5
|